News 2016-08-25
Porton Hosts An Investor Reception, August 25, 2016.
Changshou [Chongqing Metropolitan Region], China, August 25, 2016: Porton proudly hosted a delegation of >50 investment analysts and corporate finance media professionals from the Shenzhen Stock Exchange at its USFDA-inspected production facility in Changshou, The guests were hosted by Porton Vice-Presidents Mr. Richard Tao, Dr. Tim Yu and Mr. Victor Cao and toured the site, which produces and supplies custom drug intermediates and APIs for many of the world’s most well-known and respected pharmaceutical and biotechnology companies.
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
